A case of primary Epstein-Barr virus-associated cutaneous diffuse large B-cell lymphoma unassociated with iatrogenic or endogenous immune dysregulation

Journal of Cutaneous Pathology

Volumn 35, Issue 7, 2008, Pages 666-671

  Tokuda, Yasutaka ^a   Fukushima, Mana ^b   Nakazawa, Koh ^a   Oguchi, Shinji ^c   Koganehira, Yoko ^c   Yamaura, Maki ^c   Iijima, Miwako ^c   Murata, Hiroshi ^c   Uhara, Hisashi ^c   Takata, Minoru ^c   Saida, Toshiaki ^c   Katsuyama, Tsutomu ^b   Nakamura, Sigeo ^d  

^a National Hospital Organization   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 4; LATENT MEMBRANE PROTEIN 1; PREDNISONE; VINCRISTINE; VIRUS DNA;

AGED; ANAMNESIS; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BLOOD EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; FEVER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE DYSREGULATION; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LATENT VIRUS INFECTION; PATIENT COMPLIANCE; SKIN LYMPHOMA; SOUTHERN BLOTTING; TREATMENT RESPONSE; VIRUS INFECTION;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPETENCE; IMMUNOLOGIC TECHNIQUES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RNA, VIRAL; SKIN NEOPLASMS; VIRAL MATRIX PROTEINS; VIRUS LATENCY;

EID: 44949156435     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00859.x     Document Type: Article

References (16)

1. Iwatsuki K, Ohtsuka M, Harada H, Han G, Kaneko F. Clinicopathologic manifestations of Epstein-Barr virus-associated cutaneous lymphoproliferative disorders. Arch Dermatol 1997 133:1081.
2. Purtilo DT, Tatsumi E, Monolov G, Monolova Y, Harada S, Lipscomb H. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients. In Richter GW, Epstein MA, eds. International review of experimental pathology. Orland, FL:Academic Press Inc, 1985 113.
3. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for cutaneous lymphomas other then mycosis fungoides and Sezary syndrome: a proposal of the ISCL and the cutaneous lymphoma take force of EORTC. Blood 2007 110:479.
4. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994 77:791.
5. Take H, Kubota K, Fukuda T, Shinonome S, Isikawa O, Shirakura T. An indolent type of Epstein-Barr virus-associated T-cell-rich B-cell lymphoma of the skin: report of a case. Am J Hematol 1996 52:221.
6. Donner LR. Epstein-Barr virus-induced transformation of cutaneous plasmacytoma into CD30+ diffuse large B-cell lymphoma. Am J Dermatopathol 2004 26:63.
7. Oguz O, Engin B, Demirkesen C. Primary cutaneous CD-30-positive large B-cell lymphoma associated with Epstein-Barr virus. Int J Dermatol 2003 42:718.
8. Watabe H, Kawakami T, Soma Y, Baba T, Mizoguchi M. Primary cutaneous T-cell-rich B-cell lymphoma in a zosteriform distribution associated with Epstein-Barr virus infection. J Dermatol 2002 29:748.
9. Oyama T, Ichikawa K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disease: a clinicopathologic study of 22 patients. Am J Surg Pathol 2003 27:16.
10. Verma S, Frambach GE, Seilstad KH, Nouvo G, Porcu P, Margo CM. Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol 2005 32:474.
11. Bogle MA, Riddle CC, Trana EM, Jones D, Duvic M. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol 2005 53:479.
12. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005 105:3768.
13. Hummel M, Anagnostopoulos I, Korbujuhn P, Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patients and different infection incidence in low- and high-grade types. J Pathol 1995 175:263.
14. Rowe M, Lear AL, Cloom-Carter D, Davies AH, Rickinson AB. Three passways of Epstein-Barr virus gene activation from EBNA 1-positive latency in B lymphocytes. J Viol 1992 66:122.
15. Grimm T, Schneider S, Naschberger E, et al. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005 105:3263.
16. Kazu T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV+ and EBV- cases in Japanese population. Jpn J Cancer Res 2000 91:1233.